Tumour lysis syndrome: new therapeutic strategies and classificationCAIRO, Mitchell S; BISHOP, Michael.British journal of haematology. 2004, Vol 127, Num 1, pp 3-11, issn 0007-1048, 9 p.Article

Rasburicase for the treatment and prevention of hyperuricemiaYIM, Barbara T; SIMS-MCCALLUM, Rosalyn P; CHONG, Pang H et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1047-1054, issn 1060-0280, 8 p.Article

A review of tumour lysis syndrome with targeted therapies and the role of rasburicaseBOSE, P; QUBAIAH, O.Journal of clinical pharmacy and therapeutics (Print). 2011, Vol 36, Num 3, pp 299-326, issn 0269-4727, 28 p.Article

Clarifying the role of rasburicase in tumor lysis syndromeSOOD, Amy R; BURRY, Lisa D; CHENG, Doret K. E et al.Pharmacotherapy. 2007, Vol 27, Num 1, pp 111-121, issn 0277-0008, 11 p.Article

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancyHUTCHERSON, Donald A; GAMMON, David C; BHATT, Mansi S et al.Pharmacotherapy. 2006, Vol 26, Num 2, pp 242-247, issn 0277-0008, 6 p.Article

Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignanciesTRIFILIO, S. M; PI, J; ZOOK, J et al.Bone marrow transplantation (Basingstoke). 2011, Vol 46, Num 6, pp 800-805, issn 0268-3369, 6 p.Article

Safety and efficacy of rasburicase (SR29142) in a Japanese phase II studyISHIZAWA, Kenichi; OGURA, Michinori; HAMAGUCHI, Motohiro et al.Cancer science. 2009, Vol 100, Num 2, pp 357-362, issn 1347-9032, 6 p.Article

Effect of elevated serum uric acid on cisplatin-induced acute renal failureRONCAL, Carlos A; WEI MU; CROKER, Byron et al.American journal of physiology. Renal physiology. 2007, Vol 61, Num 1, issn 1931-857X, F116-F122Article

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adultsMCDONNELL, Anne M; LENZ, Kristi L; FREI-LAHR, Debra A et al.Pharmacotherapy. 2006, Vol 26, Num 6, pp 806-812, issn 0277-0008, 7 p.Article

Hemolysis and methemoglobinemia secondary to rasburicase administrationBROWNING, Linda A; KRUSE, James A.The Annals of pharmacotherapy. 2005, Vol 39, Num 11, pp 1932-1935, issn 1060-0280, 4 p.Article

Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight PatientsCLEMMONS, Amber B; ENSLEY, Elizabeth; HOGE, Stephanie et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 9, pp 1152-1158, issn 1060-0280, 7 p.Article

Consensus conference on the management of tumor lysis syndromeTOSI, Patrizia; BAROSI, Giovanni; TURA, Sante et al.Haematologica (Roma). 2008, Vol 93, Num 12, pp 1877-1885, issn 0390-6078, 9 p.Article

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemiaTRIFILIO, S; GORDON, L; SINGHAL, S et al.Bone marrow transplantation (Basingstoke). 2006, Vol 37, Num 11, pp 997-1001, issn 0268-3369, 5 p.Article

Treatment of Burkitt lymphom in adultsGERECITANO, John; STRAUS, David J.Expert review of anticancer therapy. 2006, Vol 6, Num 3, pp 373-381, issn 1473-7140, 9 p.Article

Les traitements de la goutte Molécules actuelles et à venir = Advances in gout therapyCHALES, Gérard; GUGGENBUHL, Pascal.Rhumatos. 2010, Vol 7, Num 57, issn 1771-0081, 126-132 [6 p.]Article

Rasburicase : A new approach for preventing and/or treating tumor lysis syndrome : Biochemical and clinical relevance of hyperuricaemiaBESSMERTNY, Olga; ROBITAILLE, Lauren M; CAIRO, Mitchell S et al.Current pharmaceutical design. 2005, Vol 11, Num 32, pp 4177-4185, issn 1381-6128, 9 p.Article

Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysisFENG, X; DONG, K; PENCE, S et al.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 4, pp 301-308, issn 0269-4727, 8 p.Article

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndromeVADHAN-RAJ, S; FAYAD, L. E; SHAH, J et al.Annals of oncology. 2012, Vol 23, Num 6, pp 1640-1645, issn 0923-7534, 6 p.Article

Evaluation of a Single Fixed Dose of Rasburicase 7.5 mg for the Treatment of Hyperuricemia in Adults with CancerREEVES, David J; BESTUL, Daniel J.Pharmacotherapy. 2008, Vol 28, Num 6, pp 685-690, issn 0277-0008, 6 p.Article

Tumor lysis syndrome and acute renal failure - : an increasing spectrum of presentationsMUKHERJEE, E; MUKHERJI, D; JAYAWARDENE, S. A et al.Clinical nephrology. 2007, Vol 68, Num 3, pp 186-189, issn 0301-0430, 4 p.Article

Role of i.v. allopurinol and rasburicase in tumor lysis syndromeHOLDSWORTH, Mark T; NGUYEN, Phuongthao.American journal of health-system pharmacy. 2003, Vol 60, Num 21, pp 2213-2222, issn 1079-2082, 10 p.Article

Prescription contrôlée du Fasturtec® : évaluation à un an = Evaluation after one year of Fasturtec®: controled prescriptionDESRAYAUD-JOURDAN, N; FERRIO, A. L; KATTYGNARATH, D et al.Journal de pharmacie clinique (Paris). 2004, Vol 23, Num 3, pp 135-139, issn 0291-1981, 5 p.Article

Treatment of impending tumor lysis with single-dose rasburicaseLEE, Anselm C. W; LI, Chak H; SO, Kwan T et al.The Annals of pharmacotherapy. 2003, Vol 37, Num 11, pp 1614-1617, issn 1060-0280, 4 p.Article

Modification of a reactive cysteine explains differences between rasburicase and Uricozyme®, a natural Aspergillus flavus uricaseBAYOL, Alain; CAPDEVIELLE, Joël; MALAZZI, Pascal et al.Biotechnology and applied biochemistry. 2002, Vol 36, pp 21-31, issn 0885-4513, 1Article

Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapyPESSION, Andrea; BARBIERI, Eveline; SANTORO, Nicola et al.Haematologica (Roma). 2005, Vol 90, Num 1, pp 141-142, issn 0390-6078, 2 p.Article